We are delighted to share the exciting journey of one of our talented PhD students Sara Puglioli, which has recently been covered in a CHEM article (Cell Press). Over the...
Read morePhilogen announces the publication of a study in the peer-reviewed journal “Pharmaceutics” describing the development and the in vitro/vivo characterization of a novel interferon-gamma (IFNg) based antibody fusion protein. The paper...
Read moreDr. Covelli (CMO), Dr. Elia, Dr. Ravenni, and Dr. Nadal will participate at the event in Rome. The dermato-oncology team from St. Gallen will give a presentation entitled “Intralesional administration...
Read moreProf. Dr. Dario Neri (CEO and CSO), is giving a KEYNOTE presentation on the 18th of May 2023 entitled “Antibody-Cytokine Fusions for the Treatment of Difficult-to-Cure Cancer Types: Emerging Clinical...
Read moreProf. Dr. Dario Neri (CEO and CSO) is participating as a speaker at Lund Spring Symposium.
Follow the link for more details.
Philogen announces its attendance at the 5th MidCap Conference organised by Mediobanca. Prof. Dario Neri (CEO and CSO), Laura Baldi (CFO), and Emanuele Puca (Investor Relations) will participate at the event....
Read morePhilogen announces its attendance at World ADC2023 in London. Dr. Samuele Cazzamalli (Head of Small Molecule Therapeutics at Philochem) is giving a lecture on the 14th of March 2023 entitled “Enhancing the Therapeutic...
Read morePhilogen announces its attendance at the Antibody Engineering & Therapeutics 2022. Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled “Small Molecule-drug Conjugates (SMDCs) and Antibody-drug Conjugates (ADCs):...
Read more